These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6609451)

  • 1. Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism.
    Juhan-Vague I; Conte-Devolx B; Aillaud MF; Mendez C; Oliver C; Collen D
    Thromb Res; 1984 Mar; 33(6):653-9. PubMed ID: 6609451
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced effect of exercise and DDAVP on factor VIII-von Willebrand Factor and plasminogen activator after sequential application of both the stimuli.
    Vicente V; Alberca I; Mannucci PM
    Thromb Haemost; 1984 Feb; 51(1):129-30. PubMed ID: 6426078
    [No Abstract]   [Full Text] [Related]  

  • 3. High levels of circulating von Willebrand factor inhibit the release of this protein but not of plasminogen activator after DDAVP.
    Vicente V; Alberca I; Mannucci PM
    Thromb Res; 1985 Apr; 38(1):101-5. PubMed ID: 3873723
    [No Abstract]   [Full Text] [Related]  

  • 4. Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
    Patrassi GM; Sartori MT; Casonato A; Viero ML; Pontara E; Saggiorato G; Girolami A
    Thromb Res; 1992 Jun; 66(5):517-26. PubMed ID: 1523608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of DDAVP on plasma level of factor XII.
    Nenci GG; Berrettini M; De Cunto M; Agnelli G
    Br J Haematol; 1983 Jul; 54(3):489-92. PubMed ID: 6407513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
    Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL
    Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator response after DDAVP: a clinico-pharmacological study.
    Mannucci PM; Rota L
    Thromb Res; 1980 Oct; 20(1):69-76. PubMed ID: 7193918
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH; Giddings JC; Bloom AL
    Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.
    Vicente V; Estellés A; Laso J; Moraleda JM; Rivera J; Aznar J
    Thromb Res; 1993 Apr; 70(2):117-22. PubMed ID: 8322282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the blood plasminogen activator induced by 1-desamino-8-D-arginine vasopressin with observations in von Willebrand's disease.
    Holmberg L; Nilsson IM; Wallén P; Astedt B
    Proc Soc Exp Biol Med; 1982 Jun; 170(2):126-32. PubMed ID: 6979752
    [No Abstract]   [Full Text] [Related]  

  • 12. Is the pro-adhesive activity of plasma von Willebrand factor counteracted by a physiological inhibitor of platelet adhesiveness?
    Porta M; Cagliero E; Kohner EM
    Clin Sci (Lond); 1982 Feb; 62(2):239-42. PubMed ID: 6797774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.
    Greer IA; McLaren M; Belch JJ; Lowe GD; Forbes CD
    Haemostasis; 1986; 16(1):15-9. PubMed ID: 3084364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men.
    Prowse CV; Farrugia A; Boulton FE; Tucker J; Ludlam CA; McLaren M; Belch JJ; Prentice CR; Dawes J; MacGregor IR
    Thromb Haemost; 1984 Feb; 51(1):110-4. PubMed ID: 6426076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental studies of the liberation of plasminogen activator by DDAVP].
    Jablonowski C; Klöcking HP; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):567-74. PubMed ID: 6083928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of endothelial von Willebrand factor and platelet function in diabetic patients infused with a vasopressin analogue.
    Porta M
    Diabetologia; 1982 Nov; 23(5):452-5. PubMed ID: 6816652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease.
    Holmberg L; Nilsson IM; Borge L; Gunnarsson M; Sjörin E
    N Engl J Med; 1983 Oct; 309(14):816-21. PubMed ID: 6412139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of desmopressin (DDAVP) in the preparation of improved factor VIII concentrate.
    Mikaelsson M; Nilsson IM; Cedergren B; Jonsson S; Rydberg L; Wiechel B
    Scand J Haematol Suppl; 1984; 40():93-101. PubMed ID: 6433478
    [No Abstract]   [Full Text] [Related]  

  • 19. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease.
    Mannucci PM; Canciani MT; Rota L; Donovan BS
    Br J Haematol; 1981 Feb; 47(2):283-93. PubMed ID: 6781527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDAVP in uremia.
    Vicente V; Alberca I; Macias JF; Lopez Borrasca A
    Nephron; 1984; 36(2):145-6. PubMed ID: 6420716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.